Dengue is the fastest growing mosquito-borne viral infection whose global incidence has drastically risen in the last few years. Currently, there is no direct antiviral therapy available against the dengue viruses; most of the management is aimed at maintaining adequate intravascular volume. Doxycycline, an antibiotic derived from tetracycline with broad antimicrobial and anti-inflammatory activities has been shown to possess antiviral properties. The current article reviews the role of doxycycline in the inhibition of dengue virus and the effect of doxycycline on clinical outcome in the treatment of dengue fever. The antidengue activity and anti-inflammatory activity of doxycycline may prove to be helpful in reducing the severity of clinical symptoms such as dengue fever, severe dengue hemorrhagic fever and dengue shock syndrome.